{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:07:01Z","timestamp":1791486421099,"version":"4.3.4"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022030","name":"Silence Therapeutics plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Familial hypercholesterolaemia (FH) predisposes children to the early initiation of atherosclerosis and is preferably diagnosed by DNA analysis. Yet, in many children with a clinical presentation of FH, no mutation is found. Adult data show that high levels of lipoprotein(a) [Lp(a)] may underlie a clinical presentation of FH, as the cholesterol content of Lp(a) is included in conventional LDL cholesterol measurements. As this is limited to adult data, Lp(a) levels in children with and without (clinical) FH were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Children were eligible if they visited the paediatric lipid clinic (1989\u20132020) and if Lp(a) measurement and DNA analysis were performed. In total, 2721 children (mean age: 10.3 years) were included and divided into four groups: 1931 children with definite FH (mutation detected), 290 unaffected siblings\/normolipidaemic controls (mutation excluded), 108 children with probable FH (clinical presentation, mutation not detected), and 392 children with probable non-FH (no clinical presentation, mutation not excluded). In children with probable FH, 32% were found to have high Lp(a) [geometric mean (95% confidence interval) of 15.9 (12.3\u201320.6) mg\/dL] compared with 10 and 10% [geometric means (95% confidence interval) of 11.5 (10.9\u201312.1) mg\/dL and 9.8 (8.4\u201311.3) mg\/dL] in children with definite FH (P = 0.017) and unaffected siblings (P = 0.002), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lp(a) was significantly higher and more frequently elevated in children with probable FH compared with children with definite FH and unaffected siblings, suggesting that high Lp(a) may underlie the clinical presentation of FH when no FH-causing mutation is found. Performing both DNA analysis and measuring Lp(a) in all children suspected of FH is recommended to assess possible LDL cholesterol overestimation related to increased Lp(a).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac660","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T08:21:48Z","timestamp":1668586908000},"page":"1421-1428","source":"Crossref","is-referenced-by-count":29,"title":["Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-354X","authenticated-orcid":false,"given":"Lotte M","family":"de Boer","sequence":"first","affiliation":[{"name":"Epidemiology and Data Science, Amsterdam UMC location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"},{"name":"Pediatrics, Amsterdam UMC location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-0037","authenticated-orcid":false,"given":"Barbara A","family":"Hutten","sequence":"additional","affiliation":[{"name":"Epidemiology and Data Science, Amsterdam UMC location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Diabetes & Metabolism , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-3139","authenticated-orcid":false,"given":"Aeilko H","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"Epidemiology and Data Science, Amsterdam UMC location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health, Methodology , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-5671","authenticated-orcid":false,"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Pediatrics, Amsterdam UMC location University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Diabetes & Metabolism , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"2023042102570101800_ehac660-B1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B2","volume-title":"Familial hypercholesterolemia. The metabolic basis of inherited disease","author":"Goldstein","year":"2001"},{"key":"2023042102570101800_ehac660-B3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ Res"},{"key":"2023042102570101800_ehac660-B4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0021-9150(02)00003-5","article-title":"Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia","volume":"163","author":"de Jongh","year":"2002","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"key":"2023042102570101800_ehac660-B6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"2023042102570101800_ehac660-B7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B8","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"2023042102570101800_ehac660-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.09.005","article-title":"Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care","volume":"290","author":"Ramaswami","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1399-0004.2009.01356.x","article-title":"Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project","volume":"77","author":"Taylor","year":"2010","journal-title":"Clin Genet"},{"key":"2023042102570101800_ehac660-B11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol"},{"key":"2023042102570101800_ehac660-B12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jacl.2016.08.011","article-title":"Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: frequencies, associations and predictions","volume":"10","author":"Ellis","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2023042102570101800_ehac660-B13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023042102570101800_ehac660-B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2021.08.009","article-title":"Lipoprotein(a) in hereditary hypercholesterolemia: influence of the genetic cause, defective gene and type of mutation","volume":"349","author":"Marco-Bened\u00ed","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2023042102570101800_ehac660-B16","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2023042102570101800_ehac660-B17","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2023042102570101800_ehac660-B18","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2023042102570101800_ehac660-B19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MED.0000000000000624","article-title":"Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)","volume":"28","author":"Wilson","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023042102570101800_ehac660-B20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B21","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"2023042102570101800_ehac660-B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clinbiochem.2020.09.007","article-title":"Measuring the contribution of lp(a) cholesterol towards LDL-C interpretation","volume":"86","author":"Fatica","year":"2020","journal-title":"Clin Biochem"},{"key":"2023042102570101800_ehac660-B23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C'\u200a=\u200aLDL-C\u200a+\u200aLp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2023042102570101800_ehac660-B24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/eurheartj\/ehab875","article-title":"The year in cardiovascular medicine 2021: dyslipidaemia","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042102570101800_ehac660-B25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00439-001-0628-8","article-title":"The molecular basis of familial hypercholesterolemia in the Netherlands","volume":"109","author":"Fouchier","year":"2001","journal-title":"Hum Genet"},{"key":"2023042102570101800_ehac660-B26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s004390100505","article-title":"Nomenclature for the description of human sequence variations","volume":"109","author":"den Dunnen","year":"2001","journal-title":"Hum Genet"},{"key":"2023042102570101800_ehac660-B27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2023042102570101800_ehac660-B28","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","article-title":"Lipoprotein(a)-cholesterol: a significant component of serum cholesterol","volume":"412","author":"Kinpara","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2023042102570101800_ehac660-B29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacl.2018.02.014","article-title":"Relationship between \u201cLDL-C\u201d, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide","volume":"12","author":"Viney","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2023042102570101800_ehac660-B30","doi-asserted-by":"crossref","first-page":"20620","DOI":"10.1038\/s41598-020-77689-5","article-title":"Prevalence and status of lipoprotein (a) among lebanese school children","volume":"10","author":"Gannag\u00e9-Yared","year":"2020","journal-title":"Sci Rep"},{"key":"2023042102570101800_ehac660-B31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B32","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circ J"},{"key":"2023042102570101800_ehac660-B34","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.86.11.4171","article-title":"Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis","volume":"86","author":"Utermann","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042102570101800_ehac660-B35","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B36","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1373\/clinchem.2019.308650","article-title":"Lipoprotein(a) should be measured in all individuals suspected of having familial hypercholesterolemia","volume":"65","author":"Langsted","year":"2019","journal-title":"Clin Chem"},{"key":"2023042102570101800_ehac660-B37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"2023042102570101800_ehac660-B38","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042102570101800_ehac660-B39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023042102570101800_ehac660-B40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0022-2275(20)41958-3","article-title":"Influence of short term dietary cholesterol and fat on human plasma lp[a] and LDL levels","volume":"32","author":"Brown","year":"1991","journal-title":"J Lipid Res"},{"key":"2023042102570101800_ehac660-B42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023042102570101800_ehac660-B43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2023042102570101800_ehac660-B44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042102570101800_ehac660-B45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"2023042102570101800_ehac660-B46","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","article-title":"Pediatric aspects of familial hypercholesterolemias: recommendations from the national lipid association expert panel on familial hypercholesterolemia","volume":"5","author":"Daniels","year":"2011","journal-title":"J Clin Lipidol"},{"key":"2023042102570101800_ehac660-B47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2011.06.016","article-title":"Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization","volume":"218","author":"Descamps","year":"2011","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the international FH foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"2023042102570101800_ehac660-B49","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","article-title":"Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic?","volume":"65","author":"Chan","year":"2019","journal-title":"Clin Chem"},{"key":"2023042102570101800_ehac660-B50","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/clc.22880","article-title":"Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between Scylla and charybdis","volume":"41","author":"Ellis","year":"2018","journal-title":"Clin Cardiol"},{"key":"2023042102570101800_ehac660-B52","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570101800_ehac660-B53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2021.11.004","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)","volume":"349","author":"Chakraborty","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023042102570101800_ehac660-B54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jpeds.2011.01.038","article-title":"Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias","volume":"159","author":"Guardamagna","year":"2011","journal-title":"J Pediatr"},{"key":"2023042102570101800_ehac660-B55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpeds.2020.08.042","article-title":"Should lipoprotein(a) be measured in youth?","volume":"228","author":"Kohn","year":"2021","journal-title":"J Pediatr"},{"key":"2023042102570101800_ehac660-B56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-511X-3-29","article-title":"Correlates of serum lipoprotein (A) in children and adolescents in the United States. The third national health nutrition and examination survey (NHANES-III)","volume":"3","author":"Obisesan","year":"2004","journal-title":"Lipids Health Dis"},{"key":"2023042102570101800_ehac660-B57","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s00246-018-1927-3","article-title":"Lipoprotein (a): examination of cardiovascular risk in a pediatric referral population","volume":"39","author":"Qayum","year":"2018","journal-title":"Pediatr Cardiol"},{"key":"2023042102570101800_ehac660-B58","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.CIR.84.1.160","article-title":"Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa heart study","volume":"84","author":"Srinivasan","year":"1991","journal-title":"Circulation"},{"key":"2023042102570101800_ehac660-B59","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1421\/50050608\/ehac660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1421\/50050608\/ehac660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T02:58:43Z","timestamp":1682045923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/16\/1421\/6830679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":59,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac660","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,21]]},"published":{"date-parts":[[2022,11,16]]}}}